<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943019</url>
  </required_header>
  <id_info>
    <org_study_id>Phamon 001</org_study_id>
    <nct_id>NCT01943019</nct_id>
  </id_info>
  <brief_title>Linagliptin in Schizophrenia Patients</brief_title>
  <official_title>A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiti Kebangsaan Malaysia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately one third of patients with schizophrenia show a poor response to standard&#xD;
      treatment with antipsychotic medications. This treatment resistant group of patients&#xD;
      represents a major challenge in everyday psychiatry, and consumes a disproportionate amount&#xD;
      of time from the clinicians, resulting in considerable costs to the society and government.&#xD;
      Anecdotal evidence suggests that the enzyme dipeptidyl peptidase IV (DPPIV) may be altered in&#xD;
      patients with schizophrenia, with a higher level DPPIV enzyme activity being noted. We&#xD;
      postulate that this may play a role in the neuropathology of schizophrenia patients and by&#xD;
      inhibiting the DPPIV enzyme activity with a DPPIV inhibitor such as linagliptin, we will be&#xD;
      able to improve and even ameliorate the symptoms of schizophrenic patients. However, until&#xD;
      now there have yet any studies on the potential of these inhibitors in schizophrenia&#xD;
      patients. A pilot study is thus proposed to evaluate the potential of the DPPIV inhibitor,&#xD;
      linagliptin as an adjunct in schizophrenia patients who are non-responsive to treatment,&#xD;
      which will establish the feasibility of a larger trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to obtain patients&#xD;
  </why_stopped>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS Score</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug safety</measure>
    <time_frame>3 months</time_frame>
    <description>No of adverse events recorded per patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DPP-4 enzyme levels</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Linagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age and above&#xD;
&#xD;
          -  Diagnosis of schizophrenia.&#xD;
&#xD;
          -  Clinically stable antipsychotic regimen for the last 3 months&#xD;
&#xD;
          -  A total score of 80 or greater at baseline on the Positive and Negative Syndrome Scale&#xD;
&#xD;
          -  Competent and willing to provide written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of substance dependence within the past 2 months&#xD;
&#xD;
          -  Existing relevant physical health problems: such as uncontrolled cardiovascular&#xD;
             disease and impaired liver/ renal function&#xD;
&#xD;
          -  History of diabetes&#xD;
&#xD;
          -  History of hepatic or biliary diseases / biliary obstruction&#xD;
&#xD;
          -  A serious suicide/homicide risk in the opinion of the investigator&#xD;
&#xD;
          -  Known allergy to linagliptin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maniam Thambu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusat Perubatan UKM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Kebangsaan Malaysia</name>
      <address>
        <city>Bandar Tun Razak</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>August 14, 2018</last_update_submitted>
  <last_update_submitted_qc>August 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Shaun Lee Wen Huey</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

